Acousia Therapeutics GmbH: Acousia Therapeutics to present its first-in-class hearing loss treatment program with ACOU085 at the 2nd Inner Ear Therapeutics Summit in Boston
11.5.2022 10:03:28 CEST | news aktuell GmbH | Press release
(Tübingen, Germany): ACOU085 is a proprietary, first-in-class, small-molecule otoprotective drug candidate, which is currently being tested in a Phase 1b clinical trial involving age-related hearing loss (ARHL) patients. Designed to modulate a biologically validated target – the KCNQ4-encoded Kv7.4 potassium channel, which is essential for maintaining auditory function – ACOU085 is being developed for the treatment and prevention of hearing loss for a number of acquired and inherited forms of sensorineural hearing loss.
ACOU085 is characterized by a unique dual mode of action, which provides acute functional enhancement and long-term protection for the terminally differentiated sensorineural outer hair cells. “Being invited to share the translational background and progress of our ACOU085 lead program with the hearing loss drug development community at the Inner Ear Therapeutics Summit is an exciting opportunity for us,” says Dr. Jonas Dyhrfjeld-Johnsen, Chief Development Officer at Acousia Therapeutics. “I look forward to stimulating discussions with our peers in Boston.”
In addition to receiving an invitation to present “Small Molecule, KCNQ4 Agonist ACOU085 for the Treatment and Prevention of Hearing Loss”, Dr. Dyhrfjeld-Johnsen will also participate as a panelist on the panel discussion “De-risking the Early Development Process: A Robust and Comprehensive Early Development Process Is Essential to Minimize Setbacks Faced in the Clinic” and in the workshop “Mind The Gap: Calling Out the Shortfalls in the Current Inner Ear Therapeutic Development Pathway and Illuminating Solutions”.
About Acousia Therapeutics
Acousia Therapeutics GmbH is a privately-held, clinical stage biotech company based in Tübingen, Germany. The company is dedicated to the identification and development of small molecules for effective prevention and treatment of different etiologies of hearing loss. Acousia Therapeutics develops drugs for local and systemic administration.
Contacts
Tim Boelke,
M.D.
boelke@acousia.com
+49 70712988186
www.acousia.com
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Slovak outlet Denník N republishes numerous false allegations about Alisher Usmanov that courts have already held to be unlawful13.3.2026 08:48:33 CET | Press release
(Hamburg, Germany - 12 March 2026) On 11 March 2026, the Slovak news outlet Denník N published an article concerning the alleged efforts of the Slovak government to secure the removal of two Russian nationals from the EU sanctions list. The article contained an extensive passage concerning our client, Mr Alisher Burkhanovich Usmanov. By letter dated 12 March 2026, Denník N was requested, in order to avoid court proceedings, to provide a cease-and-desist undertaking backed by a contractual penalty. “The article was published on the eve of the European Commission’s decision on the extension of the sanctions. It reads as if its authors had taken particular care to assemble, in a single piece, every factual allegation that courts have previously found to be unlawful,” said Mr Usmanov’s lawyer, Joachim Nikolaus Steinhöfel. The article contained a dozen such statements about Alisher Usmanov, even though these very allegations have for years been prohibited, retracted, deleted or corrected in
Ship parades, evening shows and partner region Liverpool The 837th HAMBURG PORT ANNIVERSARY with a top programme11.3.2026 14:02:16 CET | Press release
(Hamburg, 11 March 2026) From 8 to 10 May 2026, Hamburg is celebrating its 837th HAMBURG PORT ANNIVERSARY. The programme includes traditional highlights such as the arrival and departure parades and the unique tugboat ballet, as well as several evening shows and the fascinating fireworks display. The programme will be supplemented by new events on the water and on land. The Big Arrival Parade on Friday, 8 May, at 1:30 p.m. marks the start of the festivities and is always an unforgettable experience: more than 100 impressive ships sail up the Elbe right before the eyes of the spectators. The majestic tall ship, the Norwegian three-masted barque Statsraad Lehmkuhl, is particularly stunning. The floating Elbe stage in front of the Landungsbrücken is THE artistic anchor of the HAMBURG PORT ANNIVERSARY: Elbe in Concert presents visitors with rousing live music and impressive performances, creating a unique atmosphere against the backdrop of the harbour skyline at night. This year’s partner
fiskaltrust Launches Portugal’s only Certified Fiscalisation Middleware and CashBox10.3.2026 08:30:00 CET | Press release
Integration Partners and Commercial Partners can now access the Portuguese market through fiskaltrust's POS System API, covering full AT (Autoridade Tributária e Aduaneira) compliance.
WELEDA x Stella McCartney: Paris Fashion Week / Skin Food: 100 years of loving skin9.3.2026 13:53:38 CET | Press release
Arlesheim, 09th March 2026 During this season’s Paris Fashion Week, WELEDA is backstage at the Stella McCartney show ensuring radiant skin: make-up artists draw specifically on the trusted nurturing power of the WELEDA Skin Food range to prep and prime the runway models’ skin perfectly for make-up and create a natural glow.
Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm5.3.2026 08:54:06 CET | Press release
Aachen, Germany & Yeoju, South Korea, 5 March 2026 – Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will have the exclusive South Korean rights to Qutenza®, a topical, non-systemic, non-opioid patch treatment. In Europe, the product is indicated for the management of peripheral neuropathic pain.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom